Aurobindo Pharma has received approval from FDA for its abbreviated new drug application for the glaucoma medication dorzolamide hydrochloride (HCl) and timolol maleate ophthalmic solution in 2% and 0.5% concentrations.
The product is a generic equivalent to the reference listed drug Cosopt ophthalmic solution, from Akorn Operating Company.
FDA indicates the drug to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension who don’t respond well to beta-blockers
IQVIA estimates the market size for dorzolamide HCl and timolol maleate ophthalmic solution to have a market size of $70 million for the twelve month period ending in March 2021.
Tell Us What You Think!